A bone marrow transplant for CML (chronic myeloid leukemia) is no longer the first treatment most patients receive, but it remains the only therapy with a long track record of curing the disease outright. Today it is reserved mainly for people whose leukemia has progressed to an advanced phase, or whose disease does not respond to, or cannot be controlled by, daily targeted pills called tyrosine kinase inhibitors (TKIs).
CML is one of several hematological disorders in which the transplant question comes up, and the answer has changed a great deal over the past two decades. This guide explains who is considered for transplant, how the procedure works, and what recovery looks like.
What Is a Bone Marrow Transplant for CML?
A bone marrow transplant, more accurately called a hematopoietic stem cell transplant (HSCT), replaces a patient’s blood-forming system with healthy stem cells from a donor. The bone marrow is the spongy tissue inside larger bones where these stem cells live and produce red cells, white cells, and platelets.
For CML, the transplant is almost always allogeneic, meaning the stem cells come from another person. An autologous transplant, using the patient’s own cells, has little role in CML because the patient’s own marrow carries the leukemic clone. The aim is to wipe out the diseased marrow and let donor cells restore normal bone marrow function.
Despite the name, most stem cells today are collected from the donor’s bloodstream after growth-factor injections, rather than drawn directly from the hip bone. Umbilical cord blood is another source for some patients.
Why a Transplant Can Cure CML
CML is driven by the Philadelphia chromosome, a swap of genetic material between chromosomes 9 and 22. This creates the BCR-ABL1 fusion gene, which makes an overactive tyrosine kinase enzyme that tells myeloid cells to keep multiplying.
A transplant works in two ways. First, the conditioning chemotherapy (with or without radiation) destroys much of the leukemic marrow. Second, and more importantly, the donor’s immune cells recognize any remaining leukemia cells as foreign and attack them. This graft-versus-leukemia effect is particularly strong in CML, which is why the disease was one of the first leukemias shown to be curable by transplant.
The strength of that immune effect also explains why donor lymphocyte infusion (giving extra donor immune cells after transplant) can often bring back remission if CML returns.
Who Is a Candidate in the TKI Era?
Before TKIs such as imatinib arrived, transplant was the standard approach for fit patients with a matched donor. Now, most people in the chronic phase take a TKI (imatinib, dasatinib, nilotinib, bosutinib, or newer agents) and can expect a near-normal life expectancy without ever needing a transplant.
A transplant is generally considered in these situations:
- Blast phase CML, usually after treatment has pushed the disease back to a chronic phase.
- Accelerated phase disease that responds poorly to TKIs.
- Resistance or intolerance to two or more TKIs.
- Resistance mutations in the BCR-ABL1 gene (such as T315I) that do not respond adequately to the drugs designed to overcome them.
- Serious blood count problems, such as persistent severe cytopenias, that prevent effective TKI dosing.
Age, overall fitness, other medical conditions, and donor availability all shape the decision. In my practice, this is always a long conversation weighing the realistic risks of transplant against the risks of the leukemia itself.
CML Phases and How They Affect Transplant Decisions
CML is traditionally divided into three phases based on how many immature cells, called blasts, appear in the blood or marrow. Newer classifications place less weight on the accelerated phase, but the three-phase framework is still widely used in treatment discussions.
| Phase | Main features | Usual first approach | Role of transplant |
|---|---|---|---|
| Chronic | Few blasts; often found on a routine blood test; may cause fatigue or an enlarged spleen | TKI therapy | Only if multiple TKIs fail or are not tolerated |
| Accelerated | Rising blasts, basophils, or new genetic changes; worsening counts | TKI therapy, often a more potent one | Considered early if response is poor |
| Blast | Behaves like acute leukemia; blasts at 20% or more under WHO criteria | TKI plus chemotherapy | Recommended for eligible patients once disease is controlled |
Transplant results are best when it is performed while the disease is in a chronic phase, which is why doctors try to regain control of advanced CML before proceeding.
The Transplant Process Step by Step
1. Pre-transplant evaluation and donor search
The team checks heart, lung, kidney, and liver function, screens for infections, and performs HLA typing to find a compatible donor. Options include a matched sibling, a matched unrelated volunteer donor, a half-matched (haploidentical) family member, or cord blood.
2. Conditioning
Conditioning uses high-dose chemotherapy, sometimes with total body irradiation, to clear the marrow and suppress the immune system so the graft is not rejected. Myeloablative regimens are more intensive; reduced-intensity regimens rely more on the graft-versus-leukemia effect and may suit older or less fit patients.
3. Stem cell infusion
The donor cells are given through a central line, much like a blood transfusion. They travel to the marrow and begin to grow, a process called engraftment, which typically takes around two to four weeks.
4. Post-transplant care
Until counts recover, patients need transfusions, infection prevention, and close monitoring. Immunosuppressive drugs are given for months to reduce the risk of graft-versus-host disease.
Risks, Complications, and Recovery
Allogeneic transplant carries real risks, which is the main reason TKIs are preferred for most people. The key complications include:
- Graft-versus-host disease (GVHD): donor immune cells attack the patient’s skin, gut, liver, or other organs. It can be acute (early) or chronic (lasting months to years).
- Infections: bacterial, viral, and fungal infections are a risk while the new immune system matures.
- Organ toxicity from conditioning, including liver and lung injury.
- Relapse of CML, which is watched for closely.
- Long-term effects such as infertility, cataracts, and hormonal changes.
After transplant, quantitative PCR (qPCR) testing for BCR-ABL1 transcripts is repeated at regular intervals. A rising level can prompt early treatment with a TKI or donor lymphocyte infusion before the disease becomes clinically obvious. Many patients return to work and normal activities within the first year, although full immune recovery can take longer.
Good nutrition matters during recovery too; for general background on marrow health, see our article on whether bone marrow is healthy for you.
Key Takeaways
- TKIs are first-line treatment for nearly all people with chronic phase CML; most never need a transplant.
- Allogeneic stem cell transplant remains the only established curative option and is reserved for advanced phase disease or failure of multiple TKIs.
- The graft-versus-leukemia effect is a major reason transplant works so well in CML.
- Risks such as GVHD and infection are significant, so the decision is individualized.
- BCR-ABL1 monitoring by qPCR continues after transplant to catch any relapse early.
For a broader look at how CML fits among other blood cancers, see our overview of hematologic disorders and the leukemia guide.
Frequently Asked Questions
Is a bone marrow transplant the only cure for CML?
Transplant is the only treatment with a long record of curing CML. However, some patients who achieve a deep, sustained molecular response on TKIs can stop their medication under close monitoring and remain in remission, a state called treatment-free remission. Whether this counts as a cure is still debated, but it means transplant is not the only path to life without daily treatment.
Can I have a transplant using my own stem cells for CML?
Autologous transplant is rarely used for CML because your own marrow contains the leukemic clone, and there is no graft-versus-leukemia effect. Allogeneic transplant from a donor is the standard approach when transplant is indicated.
What if I don’t have a matched sibling donor?
Many patients find a match through unrelated donor registries. If no full match is available, a haploidentical (half-matched) family donor or umbilical cord blood can be used, and outcomes with these options have improved considerably.
Will I still take a TKI after my transplant?
Some patients, especially those transplanted for advanced phase disease, receive a TKI after transplant to lower relapse risk. Others take one only if BCR-ABL1 levels start to rise. Your transplant team will base this on your disease history and monitoring results.
How long does recovery take?
Blood counts usually recover within weeks, and most people leave the hospital within about a month. Immune recovery and regaining full energy often take six months to a year, and follow-up visits continue for years.
